Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Chronic immune-related adverse events in patients with cancer receiving immune checkpoint inhibitors: a systematic review
Carly C. Barron, Isabella Stefanova, Yevin Cha, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 8, pp. e006500-e006500
Open Access | Times Cited: 33

Showing 1-25 of 33 citing articles:

Unraveling the complex interplay between anti-tumor immune response and autoimmunity mediated by B cells and autoantibodies in the era of anti-checkpoint monoclonal antibody therapies
Sarah Soussan, Guilhem Pupier, Isabelle Cremer, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 6
Immune-related adverse events not associated with survival in advanced or metastatic gastroesophageal cancers
Omar Elghawy, Reema Patel, Abhishek Mullapudi, et al.
Journal of Chemotherapy (2025), pp. 1-7
Closed Access
Revolutionizing cancer immunotherapy: unleashing the potential of bispecific antibodies for targeted treatment
Xiaohan Guo, Yi Wu, Ying Xue, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 12
Immune‐related adverse events in non‐small cell lung cancer: Occurrence, mechanisms and therapeutic strategies
Xuwen Lin, Mei Xie, Jie Yao, et al.
Clinical and Translational Medicine (2024) Vol. 14, Iss. 3
Open Access | Times Cited: 4
Chronic immune-related adverse events arising from immune checkpoint inhibitors: an update
Kylie Fletcher, Douglas B. Johnson
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 7, pp. e008591-e008591
Open Access | Times Cited: 4
Nivolumab-induced Thrombotic Thrombocytopenic Purpura in Patients with Gastric Tube Cancer
Yuya Yoshida, Sakura Toriyabe, Hiroo Imai, et al.
Internal Medicine (2024) Vol. 63, Iss. 19, pp. 2667-2671
Open Access | Times Cited: 3
Enhancing pancreatic cancer immunotherapy: Leveraging localized delivery strategies through the use of implantable devices and scaffolds
Elahe Minaei, Marie Ranson, Morteza Aghmesheh, et al.
Journal of Controlled Release (2024) Vol. 373, pp. 145-160
Open Access | Times Cited: 3
Immune-related intestinal pseudo-obstruction caused by immune checkpoint inhibitors: case report
Yimeng Qian, Zhi Zheng, Jing Ai, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 3
Clinical Course of Neurologic Adverse Events Associated With Immune Checkpoint Inhibitors
Simone Rossi, Antonio Farina, Antonio Malvaso, et al.
Neurology Neuroimmunology & Neuroinflammation (2024) Vol. 11, Iss. 6
Open Access | Times Cited: 3
Emerging Targets and Therapeutics in Immuno-Oncology: Insights from Landscape Analysis
Kavita A. Iyer, Julian Ivanov, Rumiana Tenchov, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 11, pp. 8519-8544
Open Access | Times Cited: 2
A Case Report of Metastatic Gastric Cancer Treated with Pembrolizumab during Pregnancy
Linda Piemonti, Laura Vettor, E. Contro
Fetal Diagnosis and Therapy (2024) Vol. 51, Iss. 5, pp. 493-499
Open Access | Times Cited: 2
Phase II Trial of Adjuvant S-1 Following Neoadjuvant Chemotherapy and Surgery in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma: The PIECE Trial
Motoo Nomura, Toshifumi Yamaguchi, Keisho Chìn, et al.
Annals of Surgical Oncology (2024)
Open Access | Times Cited: 2
Prognostic relevance of immune-related adverse events in lung cancer patients undergoing immune checkpoint inhibitor therapy: a systematic review and meta-analysis
Yuchen Huang, Wananqi Ma, Dongsheng Wu, et al.
Translational Lung Cancer Research (2023)
Open Access | Times Cited: 5
Fertility Preservation in the Era of Immuno-Oncology: Lights and Shadows
Erica Silvestris, Stella D’Oronzo, Easter Anna Petracca, et al.
Journal of Personalized Medicine (2024) Vol. 14, Iss. 4, pp. 431-431
Open Access | Times Cited: 1
Clinical and prognostic significance of sPD-1 and sPD-L1 in ovarian cancer
Н. Е. Кушлинский, О. В. Ковалева, A.N. Grachev, et al.
Immunologiya (2024) Vol. 45, Iss. 2, pp. 183-192
Open Access | Times Cited: 1
Immune Checkpoint Inhibitors as First-line Treatment for Brain Metastases in Stage IV NSCLC Patients without Driver Mutations
Guillermo Suay, Juan Carlos García‐Cañaveras, Francisco Aparisi, et al.
Cancer Letters (2024) Vol. 606, pp. 217317-217317
Closed Access | Times Cited: 1
Immune checkpoint inhibition of metastatic melanoma: achieving high efficacy in the face of high toxicity
J. B. Justice, Roma Kankaria, Douglas B. Johnson
Expert Review of Clinical Pharmacology (2024), pp. 1-11
Open Access | Times Cited: 1
Association of Survival With Immune-Related Adverse Events—Time to Consider the Duration of Treatment
Yu Fujiwara, Alessio Cortellini, Abdul Rafeh Naqash
JAMA Dermatology (2024) Vol. 160, Iss. 3, pp. 368-368
Closed Access
Research Advances of Immune Checkpoint Inhibitors Related Endocrine Adverse Events
晶晶 王
Advances in Clinical Medicine (2024) Vol. 14, Iss. 02, pp. 2706-2716
Closed Access
Immunotherapy Toxicity Management in Clinical Practice
Yael Klionsky, Alexa Meara, Pankti Reid
Rheumatic Disease Clinics of North America (2024) Vol. 50, Iss. 2, pp. 229-239
Closed Access
For the Long Haul: Management of Long-Term Survivors after Melanoma Systemic Therapy
Jordyn Silverstein, Neha Goyal, Katy K. Tsai
Current Oncology Reports (2024) Vol. 26, Iss. 7, pp. 804-817
Closed Access
Tumor-infiltrating lymphocytes and immune-related adverse events in advanced melanoma
Isabella A.J. van Duin, Mark Schuiveling, Laurens S. ter Maat, et al.
Immuno-Oncology Technology (2024) Vol. 24, pp. 100714-100714
Open Access
Management of Rheumatologic Immune-Related Adverse Events (Rh-irAEs) – An Overview of Immunosuppressive Therapies
Shahin Jamal, Jenny Li, Marie Hudson, et al.
Canadian rheumatology today. (2024)
Closed Access
Management of immune-related adverse events in oncology settings
Liset C Santoya Espinosa, C MENDES
Cancer Nursing Practice (2024)
Closed Access
Crossing the Blood-Brain Barrier: Advancing Immunotherapy for Pediatric Brain Tumors
Nima Taghizadeh Mortezaei, Adrina Habibzadeh, Zahra Rahimian, et al.
Interdisciplinary cancer research (2024)
Closed Access
Page 1 - Next Page

Scroll to top